Modulation of Alzheimer's pathology by cerebro-ventricular grafting of hybridoma cells expressing antibodies against Abeta in vivo

Accumulation in brain of the beta-amyloid peptide (Abeta) is considered as crucial pathogenic event causing Alzheimer's disease (AD). Anti-Abeta immune therapy is a powerful means for Abeta clearance from the brain. We recently showed that intravenous injections of anti-Abeta antibodies led to...

Full description

Saved in:
Bibliographic Details
Published in:FEBS letters 2005-01, Vol.579 (3), p.753-756
Main Authors: Gaugler, Meret N M, Tracy, Jay, Kuhnle, Katrin, Crameri, Arames, Nitsch, Roger M, Mohajeri, M Hasan
Format: Article
Language:English
Subjects:
Alzheimer Disease - immunology
Alzheimer Disease - pathology
Amyloid beta-Peptides - immunology
Animals
Antibodies - administration & dosage
Antibodies - immunology
Cerebral Ventricles - immunology
Cerebral Ventricles - pathology
Hybridomas - immunology
Mice
Mice, Transgenic
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Accumulation in brain of the beta-amyloid peptide (Abeta) is considered as crucial pathogenic event causing Alzheimer's disease (AD). Anti-Abeta immune therapy is a powerful means for Abeta clearance from the brain. We recently showed that intravenous injections of anti-Abeta antibodies led to reduction, elevation or no change in brain Abeta42 concentrations of an AD mouse model. We report here, in a second passive immunization protocol, a different bioactivity of same antibodies to alter brain Abeta42 concentrations. Comparing the bioactivity of anti-Abeta antibodies in these two passive immunization paradigms underscores the potential of immune therapy for AD treatment and suggests that both the epitope recognized by the antibody and the mode of antibody administration are crucial for its biological activity.
ISSN:0014-5793